UNIVERSITY OF KINSHASA
🇨🇩Democratic Republic of the Congo
- Country
- 🇨🇩Democratic Republic of the Congo
- Ownership
- Private
- Employees
- -
- Market Cap
- -
- Website
- http://www.unikin.cd
Clinical Trials
3
Active:0
Completed:2
Trial Phases
2 Phases
Phase 3:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 3
1 (50.0%)Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- University of Kinshasa
- Target Recruit Count
- 166
- Registration Number
- NCT05681598
- Locations
- 🇨🇩
University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the
Comparison of ISTp- PYRAMAX-US-RDT to IPTp-SP to Prevent Malaria in Pregnant Women in DRC (ULTRAPYRAPREG)
Phase 3
Completed
- Conditions
- Malaria in Pregnancy
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- University of Kinshasa
- Target Recruit Count
- 250
- Registration Number
- NCT04783051
- Locations
- 🇨🇩
Maternité Esengo, Kinshasa, Congo, The Democratic Republic of the
COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach
- Conditions
- COVID-19
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- University of Kinshasa
- Target Recruit Count
- 800
- Registration Number
- NCT04424940
- Locations
- 🇨🇩
Cliniques Universitaires de Kinshasa, Kinshasa, Congo, The Democratic Republic of the
News
Bavarian Nordic Initiates First Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
Bavarian Nordic has launched two groundbreaking clinical trials to evaluate the safety and immunogenicity of MVA-BN mpox vaccine in 344 infants aged 4-24 months and 359 pregnant or breastfeeding women.